Home
    Disclaimer

    MD-PiHP Stats & Data

    3,4-methylenedioxy-pihp
    Chemical Class Amphetamine
    Psychoactive Class Stimulant
    Half-Life 3-7 h (no human PK; inferred from α‑PiHP/MDPHP case patterns and stimulant tails)

    Effect Profile

    Curated
    Stimulant 6.1

    Strong euphoria and anxiety/jitters with moderate focus, mild stimulation

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    10
    Focus / Productivity×2
    7
    Anxiety / Jitters×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    3-7 h (no human PK; inferred from α‑PiHP/MDPHP case patterns and stimulant tails)
    Addiction Potential
    High: pyrrolidinophenones (e.g., MDPV/MDPHP) show rapid reinforcement via dopamine/norepinephrine transporter blockade, strong redose compulsion, and psychosis risk with sleep loss/bingeing; MD‑PiHP is plausibly similar.

    Tolerance Decay

    Full tolerance 12h Half tolerance 3d Baseline ~14d

    Model inferred from binge/abstinence patterns seen with MDPV/MDPHP; exact values are illustrative for planning rest periods, not clinical PK.

    Cross-Tolerances

    MDPV
    60% ●○○
    α‑PVP / α‑PHiP
    70% ●○○
    Cocaine‑like DAT blockers
    40% ●○○

    Harm Reduction

    drugs.wiki

    - Synthetic cathinones—particularly pyrrolidinophenones like MDPV/MDPHP—are associated with compulsive redosing, insomnia, paranoia, hyperthermia and, in severe cases, rhabdomyolysis and multiorgan complications; MD‑PiHP appears to share this risk profile by structure and user reports, so strict session caps and sleep preservation are key.

    - Market monitoring shows alpha‑PHiP and MDPHP are present in Europe and can cause localized health problems; bulk seizures confirm availability of this subclass. Expect occasional mislabeling and mixtures—use professional drug checking where available.

    - Reagent kits often cannot confirm identity within the pyrrolidinophenone family; lab analysis (FTIR/GC–MS) from a drug‑checking service is preferred. Saferparty has documented MDPPP and other cathinones sold as something else, illustrating frequent misrepresentation.

    - Overheating and hot environments markedly increase risk with stimulants; plan cool‑down breaks, light clothing, and paced activity. Maintain fluids with electrolytes but avoid overhydration (rough guide: ~250 ml/hour at rest; up to ~500 ml/hour if heavily active).

    - Vasoconstriction and peripheral coldness are common; avoid additional vasoconstrictors (decongestants, nicotine binges) and monitor extremity color/temperature. If fingers/toes become pale or painful, stop use, warm gradually, hydrate, and rest.

    - For nasal use, finely crush, use your own sterile straw/spoon, alternate nostrils, and rinse with isotonic saline pre/post to reduce mucosal injury and bleeding risk.

    - For inhalation, only vaporize the freebase in glass with gentle heat; harsh flame promotes pyrolysis and toxic/by‑product inhalation. Expect very fast onset and high craving—pre‑weigh single‑use doses and lock away the rest to limit binges.

    - Sleep loss is a major driver of psychosis. Plan sessions so you can sleep within 12–18 h; if unable to sleep, prioritize hydration, food, dark/quiet environment, and non‑pharmacologic sleep hygiene. Avoid stacking downers to force sleep; seek medical care if agitation, chest pain, or >39 °C (102.2 °F) fever occurs.

    - Do not combine with MAOIs; stimulant + MAOI combinations are flagged as dangerous in harm‑reduction combo references.

    - Tramadol, DXM, and bupropion lower seizure threshold or add catecholaminergic load—avoid mixing.

    - Because formal human PK is lacking, assume interindividual variability; those with cardiovascular disease, hypertension, seizure history, or pregnancy should avoid use.

    ← Back to MD-PiHP